CATHRYN MONTGOMERY CLARY
Medical Practice in New York, NY

2005005, Mar 17, 2005

Sep 8, 2004

10/935826

Stephen Arneric - Milan MI, US
Cathryn Clary - New York NY, US
Douglas Feltner - Novi MI, US
Wilma Harrison - Harrison NY, US
Richard Kavoussi - Ann Arbor MI, US
Atul Pande - East Lyme CT, US
Charles Taylor - Chelsea MI, US

A61K031/519, A61K031/195

514220000, 514259410, 514561000

A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNRI or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.

7553847, Jun 30, 2009

Feb 13, 2006

11/352286

Cathryn M. Clary - New York NY, US
Jeroen Van Beek - Ridgefield CT, US
Perry S. Eisman - Southamton NY, US
Sean Donevan - Dexter MI, US
Atul Pande - East Lyme CT, US
Richard Kavoussi - Ann Arbor MI, US

Indevus Pharmaceuticals, Inc. - Lexington MA

A61K 31/4745

514300

The present invention provides methods for treating social anxiety disorder, comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone or pharmaceutically acceptable salt, or optical isomer therof, and optionally comprising administering another compound for the treatment of social anxiety disorder that is a GABA agonist.

2003002, Jan 30, 2003

Apr 25, 2002

10/133471

Cathryn Clary - New York NY, US
Jeroen Van Beek - Ridgefield CT, US
Perry Eisman - Southampton NY, US
Sean Donevan - Dexter MI, US
Atul Pande - East Lyme CT, US
Richard Kavoussi - Ann Arbor MI, US

A61K031/4745

514/300000

The present invention provides methods and kits for treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, anxiety associated with a medical condition, adjustment disorder with anxious mood, dysthymia, specific phobia or fibromyalgia using a compound of Formula I or a pharmaceutically acceptable salt, optical isomer or prodrug thereof The present invention also provides compositions comprising a compound of Formula I or a pharmaceutically acceptable salt, optical isomer or prodrug thereof and an additional compound useful to treat the aforementioned conditions.